Itrac

Itraconazole, the active ingredient in Itrac, is an azole antifungal presented as an oral formulation for systemic use. Approved in the European Union, it treats a variety of fungal infections such as dermatophytosis, onychomycosis, systemic candidiasis and aspergillosis in adult patients.

GNH USA supplies Itrac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product complies with EU GMP standards and is available for bulk and unit‑dose distribution across global markets.

Itraconazole is an azole antifungal that interferes with ergosterol synthesis in pathogenic fungi. - Dermatophytosis: clears skin fungal infections and reduces lesion spread. - Onychomycosis: eradicates nail‑bed infection, allowing healthy nail regrowth. - Systemic candidiasis: treats invasive Candida infections in immunocompromised patients. - Aspergillosis: controls chronic pulmonary aspergillosis by suppressing fungal growth.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Abdominal pain: intermittent stomach cramps. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Cardiac failure: new or worsening congestive heart failure. - Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.

When prescribing itraconazole, clinicians should consider several precautionary measures to ensure patient safety. - Liver function monitoring: assess baseline enzymes and repeat during therapy. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Cardiac status: avoid in patients with existing heart failure. - Pregnancy and lactation: use only if benefits outweigh risks. - Renal impairment: adjust dose in severe cases if needed. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Itraconazole has a notable interaction profile, primarily due to its inhibition of CYP3A4 enzymes.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that reduces itraconazole exposure. - Carbamazepine: enzyme inducer leading to subtherapeutic levels. - St. John’s wort: herbal inducer that markedly decreases efficacy.

Moderate Interactions (Monitor Closely): - Statins (e.g., simvastatin): increased risk of myopathy; dose adjustment may be needed. - Calcium channel blockers (e.g., verapamil): may increase itraconazole levels; monitor for toxicity.